Who founded Kymera Therapeutics?

Kymera Therapeutics was founded by Nello Mainolfi, Bruce Booth in 2016.

Who are Kymera Therapeutics's investors?

Kymera Therapeutics's investors include Atlas Venture, Avoro Capital Advisors, Bain Capital Life Sciences, Bessemer Venture Partners, Hatteras Venture Partners, MRL Ventures Fund, Nextech Invest, Pfizer Venture Investments and 6 more.

Kymera Therapeutics

NASDAQ: KYMRUnicorn · $2.3B

Founded 2016 · Incorporated in Delaware · 303 employees on LinkedIn · 14 known investors

Find your way into Kymera Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Kymera Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins. The company focuses on advancing small molecule therapies designed to address critical health problems across multiple disease areas.

Biotech Deep Tech Healthtech

Founders & leadership

Kymera Therapeutics was founded in 2016 by Nello Mainolfi and Bruce Booth.

Nello Mainolfi Founder, President and Chief Executive OfficerFounder of Kymera Therapeutics, a clinical-stage biotech developing targeted protein degradation medicines, where he works on advancing a new class of degrader therapies. He has held science, leadership, and business roles across large pharma and biotech, with experience in company creation, scaling, strategic partnerships, and private and public offerings.

Bruce Booth ChairPartner at Atlas Venture

Investors · 14

Atlas Venturelisted by Atlas VentureCambridge · $500K – $1M

How we know: Atlas Venture's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York

How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us

Bain Capital Life Scienceslisted by Bain Capital Life SciencesBoston

How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us

Bessemer Venture Partnerslisted by Bessemer Venture PartnersSan Francisco · $50K – $100M

How we know: Bessemer Venture Partners's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Hatteras Venture Partnerslisted by Hatteras Venture PartnersResearch Triangle · $500K – $4M

How we know: Hatteras Venture Partners's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

MRL Ventures Fundlisted by MRL Ventures FundCambridge · $25M

How we know: MRL Ventures Fund's portfolio page · Not right? Tell us

Nextech Investlisted by Nextech InvestZurich · $648K – $3.2M

How we know: Nextech Invest's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us

Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M

How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Solasta Ventureslisted by Solasta VenturesBoston

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Wellington Managementlisted by Wellington ManagementBoston · $5M – $50M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

6 Dimensions CapitalreportedGrand Cayman

How we know: a partner's Signal profile · Not right? Tell us

Biotechnology Value FundreportedSan Francisco

How we know: the S-1 prospectus · Not right? Tell us

REDMILEreportedSan Francisco

How we know: the S-1 prospectus · Not right? Tell us

Valuation · disclosed

Disclosed events

$2.3Bvaluation at IPOJul 2021 · $47.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

3 people who came through Kymera Therapeutics went on to found or lead other companies.

Wei LiBoard MemberFounded Quantxbio +1 John MaraganoreBoard MemberFounded Alnylam Pharmaceuticals JOANNA HOROBINNon Executive DirectorFounded Syndax Pharmaceuticals

Related companies · 3

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

Companies working in the same space as Kymera Therapeutics.

Frequently asked questions

What does Kymera Therapeutics do?: Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins. The company focuses on advancing small molecule therapies designed to address critical health problems across multiple disease areas.
Who founded Kymera Therapeutics?: Kymera Therapeutics was founded by Nello Mainolfi, Bruce Booth in 2016.
Who are Kymera Therapeutics's investors?: Kymera Therapeutics's investors include Atlas Venture, Avoro Capital Advisors, Bain Capital Life Sciences, Bessemer Venture Partners, Hatteras Venture Partners, MRL Ventures Fund, Nextech Invest, Pfizer Venture Investments and 6 more.